BenevolentAI, a leading clinical-stage AI-enabled drug discovery company, announces that AstraZeneca has selected an additional novel target for idiopathic pulmonary fibrosis (IPF) for its drug development portfolio, resulting in a milestone payment to BenevolentAI. Also Read: Tethis Launches See.d, the First Fully Automated, Standardized Pre-analytical Platform for Comprehensive Liquid Biopsy Testing This is the third novel… Continue reading Benevolentai Achieves Third Milestone in Its AI-Enabled Drug Discovery Collaboration With AstraZeneca